Alternative T-cell costimulatory pathways in transplant rejection and tolerance induction: Hierarchy or redundancy?

American Journal of Transplantation

Volumn 3, Issue 5, 2003, Pages 509-511

  Salama, Alan D ^a   Sayegh, Mohamed H ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; CD28 ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; POSTOPERATIVE COMPLICATION; PREDICTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD28; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; MICE; MODELS, BIOLOGICAL; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038246517     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00114.x     Document Type: Review

References (24)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042-1049.
2. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-1821.
3. Williams MA, Trambley J, Ha J et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000; 165: 6849-6857.
4. Rothstein DM, Livak MF, Kishimoto K et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322-329.
5. Kenyon NS, Chatzipetrou M, Masetti M et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999; 96: 8132-8137.
6. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693.
7. Yamada A, Kishimoto K, Dong VM et al. CD28-independent costimulation of T cells in alloimmune responses. J Immunol 2001; 167: 140-146.
8. Shimizu K, Schonbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000; 165: 3506-3518.
9. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13: 559-575.
10. Ozkaynak E, Gao W, Shemmeri N et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591-596.
11. Ozkaynak E, Wang L, Goodearl A et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002; 169: 6546-6553.
12. Salama AD, Yuan X, Nayer A, Chandraker A, Sayegh MH. The interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant 2003; 3: 390-395.
13. Yuan X, Salama AD, Dong V et al. The role of the CD134-CD134-L costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170: 2949-2955.
14. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168: 4897-4906.
15. + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169: 4882-4888.
16. Tan JT, Ha J, Cho HR et al. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation 2000; 70: 175-183.
17. Nozawa K, Ohata J, Sakurai J et al. Preferential blockade of CD8 (+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases. J Immunol 2001; 167: 4981-4986.
18. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw137) regulates graftversus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 2001; 166: 3174-3183.
19. DeBenedette MA, Wen T, Bachmann MF et al. Analysis of 4-1BB ligand (4-1BBL) -deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999; 163: 4833-4841.
20. + T cells. Am J Transplant 2003; 3: 543-551.
21. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-lg regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
22. Kishimoto K, Dong VM, Issazadeh S et al. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest 2000; 106: 63-72.
23. Kishimoto K, Sandner S, Imitola J et al. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest 2002; 109: 1471-1479.
24. Williams MA, Tan JT, Adams AB et al. Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol 2001; 167: 4987-4995.